You know when your favorite sports team has a high draft pick who doesn’t develop as fast as you, or the team, would like? At some point, the front office has to decide: will this player ever reach their potential, or are we better off cutting bait and focusing on somebody else? That is roughly how we feel about Protara Therapeutics (Nasdaq: TARA).
We have been writing about Protara since 2023, when the stock was $1.78. It trades around $4 today, and there have been a few moments since that first note when Protara looked ready to push meaningfully higher. It has never sustained those moves. Overall, the stock has been a laggard relative to many of its development-stage peers, during one of the best biotech markets in recent memory.
Part of the problem is the misfit nature of the assets in the pipeline. Part of it is slow clinical execution across every program. We would concede that, in most cases, the front office cuts bait on a laggard; slow-developing prospects, regardless of their draft status, rarely reach their full potential.
Yet despite all that, when it comes to Protara, we still find ourselves in the “potential” camp. We think there are approvable drugs here. The clinical hurdle for TARA-002 in lymphatic malformations (LMs) looks very achievable, and while there is regulatory risk, we would bet on eventual approval. We feel much the same about TARA-002 in BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC): the clinical hurdle is achievable, the regulatory path is well established, and the harder question is commercial viability in a crowded indication, but we think it gets approved. IV Choline Chloride is the unknown. The company has done little to emphasize it, though both the clinical and regulatory hurdles appear achievable.
So we are willing to be patient with this draft pick and give it another year to develop, while fully acknowledging it could remain a laggard for the rest of 2026. Over the course of 2027, the company should have a deluge of data that will determine whether our patience was warranted or foolhardy.
Changing The Playbook
That patience was tested again earlier this month, in a Q2 earnings release that changed the clinical strategy for TARA-002 in BCG-naïve NMIBC. Protara announced that ADVANCED-3, previously a randomized registrational study in BCG-naïve high-grade, high-risk NMIBC, is being redesigned as a multi-cohort, open-label, exploratory trial. The proposed study will evaluate TARA-002 in BCG-naïve and BCG-exposed CIS (± Ta/T1) patients, as well as papillary (Ta/T1) patients across BCG exposures, in roughly 150 patients, with six-month complete response for CIS and twelve-month disease-free survival for papillary as the readouts.
Simply put, Protara has stopped pursuing an FDA label for TARA-002 in BCG-naïve. The company’s BCG-unresponsive study, ADVANCED-2, is once again the only registrational NMIBC trial. Enrollment wraps this quarter. Approval, realistically, is a 2028 event. Everything else is now a commercial-access exercise: generate enough data across a broader high-risk population to get into the NCCN guidelines at or around launch, rather than run a randomized trial the company would have struggled to fund on its own.
Does The Guidelines Play Work?
We reviewed the NCCN bladder cancer guidelines and found that, as of its most recent update in March 2026, every approved BCG-unresponsive agent now carries a recommendation for papillary-only disease — a population outside all three of their FDA labels. Each was approved for CIS with or without papillary tumors. Each generated separate data in papillary-only patients. And in each case, NCCN listed them there anyway.
ImmunityBio’s Anktiva (nogapendekin alfa inbakicept) was added in March on 80 papillary-only patients showing 58.2% 12-month DFS. J&J’s Inlexzo (gemcitabine intravesical system) was listed on SunRISe-1 Cohort 4, 52 patients with 70.2% 12-month DFS. And Ferring’s Adstiladrin (nadofaragene firadenovec) was upgraded from 2B in a release where Ferring itself notes that the drug is not FDA-approved there and that its effectiveness in that population has not been established.
Three for three, all Category 2A — lower-level evidence, but with uniform panel consensus, defined as at least 85% support. That is a bar a single-arm, open-label study can clear, and payers follow NCCN more often than not.
Here is the part that can’t be glossed over. Every one of those expansions remained within BCG-unresponsive disease. The move was from CIS to papillary-only, within a population for whom the realistic alternative is bladder removal—exactly the setting in which guideline committees will accept single-arm data. Nobody has been guideline-extended into BCG-naïve, where BCG itself remains an effective, inexpensive, entrenched standard of care and the unmet-need argument isn’t nearly as compelling. The redesigned ADVANCED-3 bundles three quite different asks together. Papillary across BCG exposures and BCG-exposed CIS sit close to the existing precedent. BCG-naïve is a materially harder proposition.
Needs A Partner
Our view has not changed since our May 2026 note, Protara at a Crossroads: NMIBC is not an indication Protara should pursue much further on its own. However, we suspect potential partners are unlikely to pay fair value until Protara shares more complete data on TARA-002. That should change next year, when a partner evaluating TARA-002 will see mature, ADVANCED-2 BCG-unresponsive data and an exploratory dataset from ADVANCED-3, leading to a very different partnering conversation than the one held today.
As of the most recent interim data from ADVANCED-2, TARA-002’s 65.7% complete response at any time and 68.2% at six months hold up against the field; the 33.3% at twelve months does not, though it rests on just fifteen evaluable patients. Convenience is the other half of the TARA-002 pitch: no vial thaw, no urine bleaching, no elevated biosafety handling, and no pre- or post-treatment protocol. Against Adstiladrin’s three-to-ten-hour thaw or Inlexzo’s tri-weekly cystoscopic insertion and removal, that matters in community practice.
A Franchise, Not Just An Asset
We are not going to relitigate the case for TARA-002 in LMs; readers can refer to our note, Could A New Narrative Be Forming?, from November 2025. We continue to believe this is the asset best suited for Protara to take to the finish line itself. The data to date are highly compelling, and given that OK-432 is approved in Japan and Taiwan and has treated thousands of patients, we are confident the data from the ongoing STARBORN-1 study will remain strong.
What we find curious is how little credit the company receives for LMs and what sits behind an approval. Priority review voucher eligibility is one factor. Indication expansion is another. Management has openly discussed pursuing follow-on malformation and cyst indications, for which OK-432 has already demonstrated benefit, and estimates that these could reach another 12.5 million patients. That is a prevalence figure, and TARA-002’s addressable markets are incidence-driven, so discount it heavily. Nevertheless, LMs may well be the first indication of a much larger cyst franchise, reached through a concentrated prescriber base at multidisciplinary vascular anomalies centers, a group a small commercial team can call upon. It is the exact inverse of community urology.
Then there is Palvella Therapeutics (Nasdaq: PVLA), which remains a relevant LMs peer, caveats and all. We first flagged Palvella in December 2024, when it carried a $200 million valuation; it is now near $2.2 billion, an eleven-fold move in twenty months. We have covered the caveats before, and they have not changed: Palvella’s QTORIN treats microcystic LMs and is a chronic treatment with a prevalence-based TAM, whereas TARA-002 is focused on macrocystic LMs, is curative, and has an incidence-based TAM. What we have not emphasized enough is the structural difference, and we think it factors into the roughly $2 billion valuation gap as much as anything.
Palvella is a pure play. One asset, one lead indication, then indication expansion off the back of clinical success. In our experience, that is the strategy most microcap biotech investors want, and Palvella has executed it as cleanly as anyone could ask. Protara is the opposite: two assets across three wildly different indications. If you like the LMs program and believe in its expansion into other malformations, you cannot buy it separately. You have to buy the pipeline, including NMIBC and IV Choline, as well.
We keep arguing that the company gets little credit for LMs, but that is partly its own doing. NMIBC sits above it on the pipeline chart; it is the program the company is best known for and, importantly, the one through which it has raised capital. LMs has real investor appeal, in our opinion, but less so when subordinated to NMIBC. It is another argument, and maybe the most practical one, that these assets do not belong in the same company.
Waiting On NMIBC
Look at what the company has guided to for the rest of the year. Enrollment completion in ADVANCED-2 and STARBORN-1 in the fourth quarter. Additional LMs data from STARBORN-1, which in a pure-play would be the event of the year but will likely get less attention here than it deserves. THRIVE-3 interim data on IV Choline, an asset nobody is watching. That is not a thin slate by most standards. It is just that none of it is NMIBC, and NMIBC is where investor attention is focused.
Regarding NMIBC, we are fairly confident Protara will not be at the Society of Urologic Oncology (SUO) annual meeting in December. It was not mentioned in the Q2 release. That makes the ASCO Genitourinary Cancers Symposium (ASCO GU), February 11–13 in San Francisco, the next logical window. However, it would not surprise us if the next update instead comes at the American Urological Association (AUA) annual meeting, May 21–24 in San Diego. By then, the company should have roughly 50 patients evaluable at 12 months and nearly all of them at 6. Protara has some scar tissue from the low-denominator phenomenon in its last ADVANCED-2 release, where a 33.3% twelve-month landmark from 15 patients did the company no favors. We would expect the company to err on the side of waiting for a more substantive denominator before releasing additional data.
When Protara does eventually release more ADVANCED-2 data, if the anytime and six-month rates hold and the twelve-month landmark pushes north of 40%, that is a significant catalyst. To be clear, a 40% twelve-month landmark CR isn’t a regulatory bar (Adstiladrin was approved with a 24% landmark); it is our estimate of what the market wants, given investors sold the stock on 33%. In an indication this crowded, the difference between third line and fourth could be a couple hundred million in annual sales, and it turns on details like twelve-month durability. That is also the number we feel a good partner will underwrite.
Value Trap Or Coiled Spring?
At a $225 million market cap against $162 million of cash, Protara looks cheap. It may also be a value trap, and we would not argue otherwise. The company could have plenty of newsflow to end 2026, but we question whether any of it is likely to move the stock. And if we are right that the next ADVANCED-2 data comes at AUA in May, the first half of 2027 could lack a stock-moving catalyst too.
But a coiled spring and a value trap can look identical right up until the data arrives. By mid-2027, the picture changes: interim and, eventually, top-line ADVANCED-2 data, mature LM data, and a BLA filing. That is where the value creation happens, and it could be considerable. Owners today have the balance sheet and the pipeline as downside protection. What they require in the interim is patience.
Roster Decisions
Which brings us back to the draft pick. We are keeping ours for another year.
The harder question is whether Protara’s front office will make the same disciplined call about its own lineup. Every argument in this note points to the same conclusion: LMs is the franchise player this company is built to develop, NMIBC is the asset it should trade to a larger club, and IV Choline remains a utility player without a position. The pure-play discount isn’t a market quirk; it’s the league telling Protara that it’s holding a misfit roster.
We are giving our pick the year. Ask us again in 2027.